India Inc Goes Abroad - MAPE Advisory Group
India Inc Goes Abroad - MAPE Advisory Group
India Inc Goes Abroad - MAPE Advisory Group
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
The Deal Details<br />
Healthcare Sector contd.<br />
Acquirer Target Country Date Deal Size Remarks<br />
Nicholas Piramal Dobutrex Brand Rights USA Jul-04 Est. < 5.0 100% rights of Dobutrex Brand in <strong>India</strong> from Eli Lily &<br />
Company, USA<br />
Nicholas Piramal Anaesthetics business<br />
in UK<br />
UK Dec-04 14.0 100% of Rhodia’s global Inhalation Anaesthetics business<br />
based in UK<br />
Nicholas Piramal Biosyntech <strong>Inc</strong>. Canada Jul-05 4.1 17.1% stake in the Canadian biotech research company<br />
BioSyntech<br />
Nicholas Piramal Avecia Pharmaceuticals UK Oct-05 16.9 100% stake in the UK-based CMO having annual turnover of<br />
US$64.2mn<br />
Opto Circuits Medical Equipment Co. Europe Oct-05 13.3 100% stake in the US based company which is developing a<br />
novel blood glucose monitoring machine<br />
Opto Circuits Eurocor GmbH Germany Dec-05 13.0 100% stake in the German company that designs and<br />
manufactures stents<br />
Ranbaxy Bayer's Generic Drug<br />
business<br />
Germany Apr-00 Est. < 5.0 No Details available<br />
Ranbaxy Veratide Germany Jun-02 Est. < 5.0 100% of Veratide - the anti-hypertensive brand in Germany<br />
from P&G<br />
Ranbaxy Signature Pharma's<br />
Liquid manufacturing<br />
unit<br />
USA Jul-02 Est. < 5.0 100% of a liquid manufacturing facility from the New Yorkbased<br />
Signature Pharmaceuticals <strong>Inc</strong> on an asset-purchase<br />
basis<br />
Ranbaxy RPG AVENTIS SA France Dec-03 80.0 100% stake in the French company ranked fifth in generic<br />
market with a 6% market share; annual sales of EUR52.0mn<br />
Ranbaxy Efarmes - generic<br />
product<br />
Ranbaxy Terapia SA (96.70%<br />
stake)<br />
Spain Jun-05 Est. < 5.0 100% stake in a generic product portfolio accounting for<br />
eighteen products belonging to the Spanish pharmaceutical<br />
company EFARMES<br />
Romania Mar-06 324.0 96.7% stake in Romania based company having annual<br />
turnover of US$80.0mn<br />
Ranbaxy Allen SpA Italy Mar-06 Est. < 10.0 Purchase of Glaxo’s unbranded Italian generic business<br />
Ranbaxy Ethimed, Belgium Belgium Mar-06 Est. < 10.0 100% stake in a Belgian generic pharmaceutical distributor<br />
24
Change language